MeSH D006086 - graft vs host disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D007154:Immune system diseases
D006086:
Graft vs host disease
D000092122:Bronchiolitis obliterans syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
No data
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| A.H. Robins Company | Methylprednisolone | Methylprednisolone | 1982-01-01 | |||
| Prednisone | Prednisone | 1982-01-01 | ||||
| Abbott Biotherapeutics | Methylprednisolone | A-methapred | 1991-02-22 | |||
| Accord Healthcare | Mycophenolate mofetil | Mycophenolate Mofetil | 2009-05-04 | |||
| Tacrolimus | Tacrolimus | 2011-08-31 | ||||
| Alkem Laboratories | Mycophenolate mofetil | Mycophenolate Mofetil | 2011-11-04 | |||
| Tacrolimus | Tacrolimus | 2020-11-12 | ||||
| Allergan | Methylprednisolone | Methylprednisolone | 1997-10-16 | |||
| Prednisone | Prednisone | 1982-01-01 | ||||
| American Therapeutics | Prednisone | Prednisone | 1986-11-06 | |||
| Amneal Pharmaceuticals | Methylprednisolone | Methylprednisolone | 2021-09-21 | |||
| Mycophenolate mofetil | Mycophenolate Mofetil | 2010-07-16 | ||||
| Prednisone | Prednisone | 1987-10-05 | ||||
| Apotex | Mycophenolate mofetil | Mycophenolate Mofetil | 2009-04-22 | |||
| APP Pharmaceuticals | Methylprednisolone | Methylprednisolone | 1984-06-08 | |||
| Astellas Pharma | Tacrolimus | Advagraf | 2007-04-23 | |||
| Tacrolimus | Astagraf | 2013-07-19 | ||||
| Tacrolimus | Modigraf | 2009-05-15 | ||||
| Tacrolimus | Prograf | 1994-04-08 | ||||
| Tacrolimus | Protopy | 2002-02-28 |
1
2
3
4
5
6
...
10
>
Clinical Trials
Historical Success Rate
Phase 1
81%67/83
Phase 2
39%47/119
Phase 3
47%29/62
Approved: 9Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
7
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use